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Abstract
Background—The benzodiazepine receptor antagonist flumazenil reduces anxiety-like behavior
and sensitization of anxiety-like behavior in various models of ethanol withdrawal in rodents. The
mechanism and brain region(s) that account for this action of flumazenil remain unknown. This
investigation explored the potential role of several brain regions (amygdala, raphe, inferior colliculus,
nucleus accumbens, and paraventricular hypothalamus) for these actions of flumazenil.
Methods—Rats were surgically implanted with guide cannulae directed over the brain region of
interest and then treated with an ethanol diet for three 7-day dietary cycles (5 days on ethanol diet
followed by 2 days on control diet). At approximately 4 hours, flumazenil was administered
intracranially into each of the first 2 withdrawals. Examinations of anxiety-like behavior followed 1
week later during a third withdrawal. In other animals, restraint stress sessions or intra-amygdala
DMCM (methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate) injections, preceded by
intraperitoneal flumazenil injections, were substituted for the first 2 ethanol treatment cycles to assess
the potential anxiety-sensitizing action of stress or a benzodiazepine receptor inverse agonist,
respectively.
Results—Flumazenil treatment of the amygdala during the first 2 withdrawals blocked the
development of sensitized anxiety seen during a third withdrawal. Similar actions of flumazenil were
found when stress sessions substituted for the first 2 cycles of ethanol exposure and withdrawal.
Amygdala treatment with DMCM magnified the anxiety response to the single subthreshold chronic
ethanol treatment, and prophylactic flumazenil blocked this effect.
Conclusions—Intra-amygdala flumazenil inhibits the development of anxiety sensitized by
repeated ethanol withdrawal, stress/ethanol withdrawal, or DMCM/ethanol withdrawal. These
actions suggest that site-specific and persistent effects of flumazenil on γ-aminobutyric acid-
modulatory processes in this brain region are relevant to sensitized behavioral effects seen in
alcoholism.
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Withdrawal from alcohol (ethanol) induces anxiety-like states across various animal models
and probably mimics an analogous state seen in a large proportion of alcoholics (Brady and
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Lydiard, 1993; Kosten and O’Connor, 2003; Regier et al., 1990). This negative emotional state
may be a precipitant of excessive drinking and increases the risk of relapse in alcoholics (e.g.,
reviewed in Bradizza et al., 2006). In animal models, one strategy used to block both the acute
expression of anxiety seen during ethanol withdrawal and the development of anxiety over
repeated cycles of chronic ethanol exposure is to administer the benzodiazepine receptor
antagonist flumazenil (e.g., Criswell and Breese, 1993; File et al., 1989; Knapp et al., 2004,
2005, 2007; Little, 1991; Moy et al., 1997, 2000). That a benzodiazepine antagonist with
unquestionably clear actions against benzodiazepine agonists shares anxiolytic actions with a
benzodiazepine agonist like diazepam seems paradoxical and uncertainty remains as to how
flumazenil exerts these effects (Adinoff et al., 1996; Barnard et al., 1998; Britton et al.,
1988; Buck et al., 1991; Criswell and Breese, 1993; Little et al., 1985; Moy et al., 1997,
2000). Discussions have focused on γ-aminobutyric acid (GABA)-modulatory neuroactive
steroid effects, antagonism of endogenous benzodiazepine receptor inverse agonists (which
may vary as a function of chronic ethanol exposure) and differential intrinsic activity at
benzodiazepine receptor subtypes (see Barnard et al., 1998 for summary), which are known to
change their relative abundance as a function of chronic alcohol exposure (e.g., Cagetti et al.,
2003; Devaud et al., 1995; Follesa et al., 2003; Grobin et al., 2000). Although the half-life of
flumazenil is exceedingly short (16 minutes, Lister et al., 1984; 12 to 20 minutes in human
brain, Lassen et al., 1995), its actions appear to far outlast its presence (e.g., Knapp et al.,
2005). This profile is consistent with the possibility that flumazenil’s effects include long-term
modification of an adaptive process that is central to anxiety and ethanol withdrawal. This
action has been described as “resetting the state” of the GABA-receptor complex (Buck et al.,
1991; Gonsalves and Gallager, 1988; Knapp et al., 2005; Little, 1991; Moy et al., 2000; Potokar
et al., 1997), but further details of this potential mechanism have not emerged.
Whatever its mechanism(s) of action, flumazenil can block ethanol withdrawal-induced
anxiety not only acutely (e.g., File et al., 1989, 1992; Knapp et al., 2004, 2005; Moy et al.,
1997, 2000) but also prophylactically whereby treatments from 1 to 10 days prior to withdrawal
also exert anxiolytic (Breese et al., 2004; Knapp et al., 2005) or anticonvulsant actions (Buck
et al., 1991) during withdrawal. The consistent functional effects of flumazenil on emotional
responding and similar actions of other drugs injected into the amygdala in related models
(Overstreet et al., 2006) strongly suggest that limbic regions including the amygdala and/or
extended amygdala (i.e., anxiety-related circuitry) could be involved in flumazenil’s effects.
Cycling of chronic ethanol treatments sensitizes anxiety-like behavior (Holter et al., 1988;
Overstreet et al., 2002) in a fashion that mimics kindling effects of such treatments on seizures
or withdrawal severity in animals (McCown and Breese, 1990) and in humans (Ballenger and
Post, 1978; Brown et al., 1988; Malcolm et al., 2000) (although the sensitized anxiety effect
has not been found by all researchers (e.g., Borlikova et al., 2006; Duka et al., 2002). Regardless
of whether these two phenotypes develop concurrently, it is likely that ethanol-sensitized
anxiety-like behavior and ethanol-kindled seizures arise from the activity of different brain
regions. The preponderance of evidence has shown a progressive worsening or “kindling” of
various withdrawal symptoms that may arise more readily after repeated ethanol exposure than
after continuous exposure (e.g., Becker and Hale, 1993; Booth and Blow, 1993; Lechtenberg
and Worner, 1991; McCown and Breese, 1990; Moak and Anton, 1996; Overstreet et al.,
2002). In this regard, in a model characterized by cycled withdrawal-induced sensitization of
social-interaction deficits, the withdrawal behavior can be antagonized by peripheral
administration of drugs that antagonize corticotropin-releasing factor-type 1 or 5-
hydroxytryptamine (5-HT)2C receptors or stimulate benzodiazepine, GABA-B, or 5-HT1A
receptors (e.g., Knapp et al., 2005, 2007; Overstreet et al., 2003, 2004). Comparable actions
do not appear to arise following administration of some agents that modify specific actions of
glutamate (Knapp et al., 2007); however, the multiplicity of agents with ameliorative effects
points to the relative richness of potential targets that may modify the alcoholic process, at
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least in its early stages. This investigation was conducted to explore the potential role of several
brain regions of relevance to ethanol actions in models of anxiety (Overstreet et al., 2006),
stress (Lee and Rivier, 1997), seizures (McCown and Breese, 1990), and reward (Di Chiara
and Imperato, 1985; Engel and Liljequist, 1976; Weiss et al., 1993; Woodward et al., 1999) in
the action of flumazenil to prevent anxiety sensitization arising after repeated ethanol
withdrawals. Because results suggested activity within the amygdala, the potential inhibitory
role of flumazenil against stress-sensitized withdrawal and inverse agonist activity in this
region was also studied.
METHODS
Animals
Male Sprague–Dawley rats (Charles-River, Raleigh, NC) were obtained between 160 and 180
g and housed in groups of 3 or 4 for several days to adapt to the local conditions (at 22°C and
40% humidity; light:dark cycle of 12:12 with lights on between 7 AM and 7 PM. After the rats
were adapted to these conditions for 5 days, surgeries were performed as described below.
Animals were individually housed and, after a 7-day recovery period, placed on a nutritionally
complete lactalbumin–dextrose diet and ultimately microinjected centrally as per the strategies
below. All procedures involving animals described herein were approved by the Institutional
Animal Care and Use Committee at the University of North Carolina at Chapel Hill.
Surgery
Surgery was performed under pentobarbital [50 mg/kg, intraperitoneal (i.p.)] anesthesia with
methyl atropine (2 mg/kg, i.p.) to reduce respiratory secretions. Once anesthetized, the rat was
placed in a stereotaxic instrument (Kopf Instruments, Tujunga, CA). After exposing the dorsal
surface of the skull, holes were drilled in the skull at the appropriate locations, and cannulae
were inserted at the appropriate depth (Fig. 1). Jeweler’s screws were implanted into the skull,
and dental acrylic was applied to secure the cannulae to the skull. All cannulae were made from
26-gauge stainless steel tubing. Once recovered from anesthesia, the rats were given
acetaminophen (children’s Q-Pap, cherry flavor, 6 mg/ml) in the drinking water for 48 hours.
After recovery, animals were individually housed and allowed 3 to 4 days to recover before
proceeding to experimental treatments.
Ethanol and Control Diets
At the start of dietary treatments, standard chow was taken away and a calorically balanced
and nutritionally complete liquid diet containing 4.5% ethanol (e.g., Frye et al., 1981; Knapp
et al., 2005; Moy et al., 1997, 2000; Overstreet et al., 2002) was administered in 1 of 2 protocols
depending on the experiment (Fig. 1). In the first protocol (cycled), ethanol diet was
administered for a period of 5 days followed by 2 days of withdrawal during which all animals
received control liquid diet. This procotol was then repeated twice for a total of 3 cycles. Four
hours after the ethanol was withdrawn during the first and second cycles (days 6 and 13),
animals were treated with drug or vehicle (see below). In the second protocol (noncycled), rats
received control diet during the period in which the cycled rats had experienced 2 cycles—i.e.,
the first 2 weeks. Rats were injected twice with methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-
carboxylate (DMCM) at the same time (days 6 and 13) as animals in the first protocol
experienced the onset of ethanol withdrawal. However, at the end of this 2-week period,
animals in protocol 2 received a single 5-day cycle of ethanol diet for the first time. The target
withdrawal for behavioral assessments for both protocols was this third (protocol 1) or first
and only (protocol 2) withdrawal at the end of the 3-week period. Behavioral assessments were
made between 5 and 6 hours after the removal of the ethanol based on the consistent expression
of anxiety-like behavior and zero blood ethanol levels seen at this time (e.g., Breese et al.,
2004; Knapp et al., 1998; Moy et al., 2000; Overstreet et al., 2002). In both protocols, groups
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of rats maintained on control diet were given a volume of diet equivalent to the average volume
consumed the previous day by the rats maintained on the ethanol diet. The rats were weighed
at weekly intervals, and volumes of diet were adjusted to ensure that the groups had similar
body weight gains.
Intra-brain Injections
Rats maintained on ethanol diet were injected with vehicle or flumazenil into relevant brain
sites at approximately 4 hours after the ethanol was withdrawn during the first and second
cycles. Some groups were injected with DMCM (0.3 μg μl) into the amygdala while being
maintained on control diet. For central drug injections, all injection needles were made from
32-gauge stainless steel tubing, and injections were made over 2 minutes with an additional
30 seconds before the removal of the needle from the site. Before and after injections, cannulae
were kept closed with stainless steel plugs (32-gauge wire) which were inserted into the
cannulae to a point 0.5 mm beyond the cannulae tips. To prevent damage to the targeted brain
regions, the cannulae were placed from 1.5 to 4.5 mm above the injection site, depending on
the target, and the smaller gauge injection needles projected past the cannulae tips to the areas
of interest. Injections were directed at 1 of 5 brain sites depending upon the experiment (see
below). Figure 1 provides further details of the specific cannulae coordinates for each site. For
the amygdala, nucleus accumbens, and inferior colliculus, injections were bilateral with two
cannulae inserted vertically into the brain. Injections were 1 μl per side (2.5–10 μg μl or 2.5–
10 μg per injection). Because the dorsal raphe and paraventricular nucleus sites are small
midline structures, bilateral injections were not needed and smaller volumes were used to limit
drug spreading to the surrounding brain regions. These cannulae were angled to the midline
location from a drill hole on the right side of the skull to avoid the superior sagittal sinus.
Injections for these sites were 0.5 μl (5 μg μl or 2.5 μg per injection). Overall, choices of
concentration ranges and volume ranges were based on the literature (e.g., Da Cunha et al.,
1999;Mazarati and Wasterlain, 2002;McCown et al., 1987;Pesold and Treit, 1994,1995) and
based on our previous experience with successful central injections in the amygdala (e.g.,
Overstreet et al., 2006) and other regions.
Social-Interaction Test
At approximately 5 hours after the fifth (experiments 7 to 9) or 15th and last day of ethanol
exposure (experiments 1 to 6), pairs of rats were placed in the social-interaction test. The social-
interaction test is an efficient and validated index of anxiety-like behavior in the rat (File and
Seth, 2003) and is quite sensitive to the consequences of chronic ethanol exposure (Breese et
al., 2004; File et al., 1989; Knapp et al., 2007; Overstreet et al., 2002). Briefly, the test involves
monitoring the social behavior of 2 weight-matched and similarly treated male rats placed
concurrently in an open-field apparatus (60 cm by 60 cm, with 16 equal-sized squares marked
out on the floor) for 5 minutes. Statistical analyses of several previous data sets revealed that
scoring individual animals in the pair yielded the same statistical outcome as treating the scores
of the pair as a unit (Overstreet et al., 2003, 2004). Further, control diet-treated animals that
underwent the surgery for cannulae placement were found to have normal levels of social-
interaction when compared with nonimplanted controls (Breese et al., 2007; Overstreet et al.,
2006); thus, reference animals treated with control diet received comparable handling
experiences in lieu of surgeries. Behaviors contributing to the score for each animal in the pair
included grooming the partner, closely following, crawling over/under, sniffing, and boxing.
Behaviors were scored by observers blind to the experimental condition. A forward locomotion
score (i.e., the number of 2 forepaw line crossings) that provides a general activity measure
independent of social-interaction was simultaneously recorded (File and Seth, 2003; Overstreet
et al., 2002, 2003).
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Within 48 hours of completion of the study, rats were anesthetized with pentobarbital for the
determination of the locations of the cannulae, 0.5 μl of 0.5% methyl green dye was injected
into the cannulae using the same injectors previously used to deliver the drugs, and animals
were euthanized. The brain was removed, and the location of the dye was recorded. Only rats
with correct cannulae locations were used in the statistical analyses.
Stressor
A subgroup of rats was stressed twice during the exposure to the control liquid diet. The stress
sessions consisted of restraining rats for 60 minutes (6 days apart) in plastic conical decapicones
prior to ethanol exposure to a single 5-day cycle of ethanol diet (Breese et al., 2004). In this
fashion, the restraint stress substituted for the first 2 withdrawal experiences. A subgroup was
treated intra-amygdalarly with flumazenil as described further below.
Drugs
For i.p. injection, the benzodiazepine receptor antagonist flumazenil (RO15-1788; a gift of
Hoffman, La Roche, Nutley, NJ) was prepared as a suspension in 0.5% carboxymethylcellulose
and injected at a dose of 5 mg/kg (2.5 mg/ml). For intra-amygdala injections, concentrations
of 2.5–5 μg μl were prepared as a fine suspension in artificial cerebrospinal fluid (aCSF, pH
7.4). For Experiment 5 (inferior colliculus), an additional, higher dose (10 μg μl) was also
included. The benzodiazepine receptor inverse agonist DMCM (RBI, Natick, MA) was
prepared as a fine injectable suspension at a concentration of 0.3 μg μl in aCSF using a micro
mortar and pestle.
Protocol
The study consisted of eight experiments. Experiments 1 to 6 were designed to test the ability
of the benzodiazepine receptor antagonist flumazenil to reduce ethanol withdrawal-induced
anxiety by direct injection into specific brain regions. These 6 experiments targeted the
amygdala (including dose–response effects; experiments 1 and 2), dorsal raphe (experiment
3), paraventricular nucleus of the hypothalamus (experiment 4), nucleus accumbens
(experiment 5), and inferior colliculus (experiment 6), respectively. It was previously shown
that the benzodiazepine receptor inverse agonist DMCM potentiated ethanol withdrawal-
induced anxiety-like behavior when given systemically (Knapp et al., 2005). This report also
showed that flumazenil given systemically can counteract this anxiogenic effect. Thus, in the
present study, two additional experiments (7 and 8) were conducted to test whether DMCM
injected directly into the amygdala would have the same anxiogenic properties, and whether
flumazenil given systemically would counteract these effects. Two injections 1 week apart
were given while animals were maintained on control diet. After the second drug
administration, animals were placed on one 5-day cycle with 4.5% ethanol diet. Social-
interaction testing was performed 5 hours into withdrawal at the end of the fifth day of this
cycle. Thus, all behavioral testing was done in a drug-free state. Finally, given that peripherally
administered flumazenil antagonized the ability of stress to sensitize ethanol withdrawal-
induced anxiety (Breese et al., 2004), experiment 9 assessed the ability of intra-amygdala
flumazenil to block this effect of stress.
Data Analysis
Statistical analyses of social-interaction time and locomotor behavior were carried out using
the GBStat software package (Dynamic microsystems, Inc., Silver Spring, MD). The data were
initially analyzed by one-way analyses of variance (ANOVAs). If the main effects were
statistically significant (p < 0.05), post hoc analyses of significant group comparisons were
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performed using Tukey’s protected t-tests (p < 0.05). Body weight and ethanol intake data were
analyzed with appropriate ANOVA or t-tests.
RESULTS
Effects of Repeated Amygdala Injections of Flumazenil During Withdrawal on Anxiety-Like
Behavior: Dose–Response Relationship
The results of bilateral injections of flumazenil into the amygdala are shown in Figs. 2 and 3.
Figure 2 shows data from the initial study where there was a significant effect of treatments
[F(2,34) = 38.4, p < 0.0001] and blockade of the withdrawal effect by intra-amygdala
flumazenil injections (5 μgμl per side during the first 2 withdrawals significantly blocked the
anxiety effect seen during a third withdrawal). Subsequently, doses of 2.5, 5, and 10 μg μl were
examined to confirm this effect and to isolate the optimum dose for subsequent studies. Again,
as shown in Fig. 3, there was a significant effect of treatments [F(4,22) = 7.23, p < 0.01] and
significant blockade of the repeated withdrawal effect by flumazenil with the dose–response
range appearing to lie between 0 and 5 μgμl. No additional benefit was seen with the higher
dose of 10 μg μl. No treatment significantly altered locomotor behavior in these two
experiments (data not shown).
Regional Specificity of Flumazenil Action Against Repeated Ethanol Withdrawal-Induced
Anxiety-Like Behavior
The responses to flumazenil found after injections into other brain regions are shown in Figs.
4–7. First, significant effects were found across the groups in each of the respective experiments
involving the raphe [F(2,25) = 14.53, p <0.001] (experiment 3, Fig. 4), paraventricular nucleus
of the hypothalamus (PVN) [F(2,21) = 6.31, p < 0.01] (experiment 4, Fig. 5), nucleus
accumbens [F(2,18) = 11.74, p < 0.001] (experiment 5, Fig. 6), or inferior colliculus [F(3,35)
= 13.12, p < 0.001] (experiment 6, Fig. 7). However, while the prophylactic flumazenil injected
into the amygdala strongly inhibited the social-interaction deficits caused by repeated exposure
and withdrawal from ethanol diet, injections into these other brain regions were ineffective.
None of the groups of animals in these experiments exhibited an effect of treatment on
locomotor behavior (data not shown).
Repeated Amygdala DMCM Actions on Repeated Ethanol Withdrawal-Induced Anxiety-Like
Behavior
Across treatment groups in experiment 7, there were significant effects [F(2,31) = 11.52, p <
0.001] (Fig. 8) with DMCM injections into the amygdala in lieu of the first 2 cycles of ethanol
treatment and withdrawal mimicking the effect of repeated withdrawal on anxiety-like
behavior. Compared with control-diet treated animals or animals exposed to a single 5-day
cycle of ethanol diet and withdrawal, these DMCM-treated and withdrawn animals fared worse.
While there was no effect of withdrawal alone on social interaction, there was a moderate effect
of the single cycle of ethanol exposure on locomotor behavior (p < 0.01) that was not seen in
DMCM-treated animals. Significant effects on social-interaction behavior also arose in
experiment 8, where peripheral flumazenil treatments preceded the amygdala DMCM
injections [F(3,35) = 32.52, p < 0.001] (Fig. 9). Here, flumazenil DMCM-treated and
withdrawn animals showed no social-interaction deficit relative to controls or animals exposed
only to the single cycle of ethanol diet. Locomotor effects were not significantly different
among the groups in this study (data not shown).
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Effects of Intra-amygdalar Flumazenil on Stressor Sensitized Ethanol Withdrawal-Induced
Anxiety
To assess the similarities among withdrawal, stress, and DMCM treatment effects, a subgroup
of animals was pretreated with flumazenil, (15 minutes) prior to 60 minutes of restraint stress
on 2 occasions 6 days apart. Rats were then exposed to the ethanol diet for 1 cycle of 5 days,
prior to behavioral testing during withdrawal. Significant effects were seen across treatment
groups [F(2,26) = 8.28, p < 0.001] (Fig. 10). Rats that usually show no significant anxiety-like
response to such a short ethanol exposure period became responsive, if they had a history of
exposure to a stressor. This effect was prevented by pretreating the animals with intra-
amygdalar flumazenil prior to each stressor session. Locomotor effects were not significantly
different among the groups (data not shown).
Body Weights and Alcohol Intake
All animals readily gained weight throughout the course of dietary manipulation, and
reasonable control was obtained over body weights across the various groups within and across
experiments (Table 1). Rats generally consumed between 7.5 and 9 gkgd of ethanol.
DISCUSSION
The results of these experiments indicate that flumazenil can selectively affect an index of
anxiety-like behavior while exerting no major effects on locomotor behavior in a model of
repeated ethanol withdrawal-induced anxiety. Importantly, this effect appears to be brain site
specific as well. One site of relevance appears to be the amygdala, at least so far as ethanol
withdrawal-induced anxiety-like behavior is concerned. The results also suggest that
flumazenil’s action may be specifically mediated within the amygdala rather than the
paraventricular nucleus of the hypothalamus, nucleus accumbens, inferior colliculus, and
dorsal raphe. These results complement and extend findings that peripherally administered
DMCM and flumazenil in ethanol withdrawal-related models regulate anxiety-like behavior
(e.g., File et al., 1989; Knapp et al., 2005; Moy et al., 1997, 2000) and that the amygdala is
involved more generally in withdrawal-related emotional responding (e.g., Lack et al., 2005;
Overstreet et al., 2006; Rassnick et al., 1993).
While limited in scope, the stressor experiment reiterates that exposure to a stressor likely
mimics to some extent the actions of withdrawal to sensitize neuroadaptations that render
animals more likely to express a negative emotional response during withdrawal (see also
Breese et al., 2004, 2005a; Weiss et al., 2001). More specifically, repeated restraint stress
applied prior to chronic ethanol exposure or a single stress during forced abstinence from
repeated ethanol exposure rendered animals more likely to express elevated anxiety-like
behavior during withdrawal or during abstinence (Breese et al., 2004, 2005b). The antagonistic
effect of intra-amygdalar flumazenil administration on sensitized anxiety-like response during
withdrawal suggests that both stress and chronic ethanol/withdrawal-associated mechanisms
within the amygdala contribute to this maladaptation. In this regard, it is notable that flumazenil
may also exert anxiolytic effects under conditions that would appear to induce relatively high
levels of stress or anxiety, such as in the shuttle-box avoidance procedure (Criswell and Breese,
1993). Overall, these interactions may exacerbate the course of development and maintenance
of alcoholism through effects on craving and relapse (e.g., see Breese et al., 2005a; Le et al.,
2000; Sinha, 2001). Stress experienced prior to, during, or after chronic ethanol exposure may
exert relevant effects on these processes.
While the effect of flumazenil and its site of action appears clear enough, several caveats should
be borne in mind in interpreting the data. First, the clinical data on the utility of flumazenil in
treating alcoholics are mixed. For example, in a small trial of flumazenil in ethanol-withdrawn
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subjects, Potokar et al. (1997) found that flumazenil was neither anxiolytic nor anxiogenic,
although total withdrawal scores were reduced. In contrast, Gerra et al. (1991) found anxiolytic
effects of flumazenil in withdrawing alcoholics. It is possible that more established alcoholics
or animals with more intensive exposure to ethanol are more resistant to flumazenil’s beneficial
actions, although the consistent ameliorative actions of flumazenil across a host of studies and
laboratories argue against this point (Breese et al., 2004; Buck et al., 1991; Criswell and Breese,
1993; File et al., 1989, 1992; Knapp et al., 2004, 2005, 2007; Little, 1991; Moy et al., 1997,
2000). Better isolation of the relevant mechanism should assist in focusing pharmaceutical
development on new drugs that might find more consistent utility in humans. It should also be
noted that the action of flumazenil appears to apply broadly across various chronic ethanol
treatment regimens; therefore, the uniqueness of the effect to a cycled chronic ethanol paradigm
should not be overemphasized. Further, the potential importance of brain regions other than
the amygdala and doses other than those used herein cannot be ruled out, particularly when
considering potential spread of the drug away from the injector site. In the amygdala, for
example, drug may well have reached the central, basolateral, and/or medial nuclei, and
determining whether one or more of these contributed to the effects found will require more
focused study to ascertain their potential impact on the stress-, DMCM-, or ethanol withdrawal-
sensitized response. Further considerations of the exact flumazenil concentration that reaches
the relevant receptors become all the more interesting, in that the action of flumazenil may
shift toward an agonist profile at higher doses (e.g., Barnard et al., 1998; Criswell and Breese,
1993; Knoflach et al., 1996; Skerritt and Macdonald, 1984), a possibility that complicates a
full interpretation of data from the current studies. These caveats notwithstanding, the
sensitivity of the amygdala to these manipulations (in which flumazenil was administered at
doses as low as 2.5 μgμl per side) was conclusively demonstrated in the current studies.
The mechanism through which flumazenil exerts these effects is unknown, but interesting and
not necessarily opposing ideas have emerged. The first possibility is that flumazenil may block
an endogenous benzodiazepine receptor inverse agonist that was more active and/or present in
greater amounts during withdrawal (e.g., the anxiogenic peptide diazepam-binding inhibitor)
(Katsura et al., 1995a,b, 1998; Mohri et al., 2003, but see Adinoff et al., 1996; Roy et al.,
1990). A second idea relates to the involvement of GABA-modulatory neurosteroids in chronic
ethanol effects (Cagetti et al., 2004; Devaud et al., 1995; Korpi et al., 2001). For example,
Devaud et al. (1995) found that lowered seizure thresholds induced by ethanol withdrawal were
ameliorated by the neuroactive steroid 3α-hydroxy-5α-pregnan-20-one (3α, 5α-THP,
allopregnanolone) and that sensitivity to this steroid increases with chronic ethanol exposure
(Devaud et al., 1996). This profile is reminiscent of flumazenil’s actions in control rats versus
chronic ethanol-treated rats. One interpretation consistent with each of these potential
mechanisms is that changes in GABA receptor subunit compositions after chronic ethanol
exposure endow these agents with different intrinsic activity. Flumazenil appears to be
particularly relevant to α4 subunit-containing GABA receptors (Barnard et al., 1998; Wallner
et al., 2006). Given that this subunit may increase in some brain regions after chronic ethanol
exposure (e.g., Devaud et al., 1995; Follesa et al., 2003; Sanna et al., 2003), it is possible that
functional effects of flumazenil that are unique to withdrawn animals may hinge at least in part
on this mechanism. Moreover, a “switch” from a predominantly antagonist activity to one that
includes agonist activity (at least so far as these specific α4-containing receptors are concerned)
may be responsible for the switch from a relatively innocuous antagonist in many models to
an active agonist in models incorporating chronic ethanol-treated tissue (Follesa et al., 2006;
see also Barnard et al., 1998; Wafford et al., 1996; Whittemore et al., 1996, but see Papadeas
et al., 2001). Finally, another potential mechanism that may be engaged by flumazenil involves
an interaction with adenosine. Adenosine effects during acute and chronic ethanol exposure
are well described (Diamond et al., 1991; Mailliard and Diamond, 2004), and flumazenil
reportedly antagonizes adenosine uptake in various brain regions (e.g., Phillis and Stair,
1987; Stone, 1999), an effect that would decrease neurotransmitter release. Systematic
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assessments of these respective mechanisms within the relevant brain regions (e.g., subnuclei
of the amygdala and cells therein) should provide new insight into the neural regulation of
emotional phenotypes aroused by cycles of chronic ethanol exposure.
CONCLUSION
Repeated ethanol withdrawal or repeated stresses prior to ethanol withdrawal sensitizes
anxiety-like behavior. These effects are attenuated by pretreating these manipulations with
flumazenil in the amygdala but not in a number of other brain regions. In contrast, pretreating
the amygdala with the benzodiazepine receptor inverse agonist DMCM prior to ethanol
exposure sensitizes anxiety-like behavior during withdrawal. Although other interpretations
are possible, the results are consistent with the idea that benzodiazepine inverse receptor agonist
action in the amygdala during withdrawal or stress/withdrawal sensitizes emotional
responding.
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Schematic of treatment and testing strategies (A) and digital photomicrographs (top panel)
illustrating targeted areas/needle tracks and schematics (bottom panel) showing representative
positive locations of injections into (a) amygdala, (b) dorsal raphe, (c) nucleus accumbens, (d)
paraventricular nucleus of the hypothalamus (PVN), (e) inferior colliculus (B). For cannula
placements, all measurements are in millimeters, except for the angle of approach, which is
measured in degrees from vertical.* All coordinates are relative to Bregma, except for the
raphe, which is relative to lambda, and the inferior colliculus where the anterior–posterior (AP)
location was defined as 0.2 mm anterior to the interaural line. CD, control diet; ED, 4.5%
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ethanol diet; ML, medial lateral; DV, dorsoventral. Coordinates and anatomical schematics are
from Paxinos and Watson (2005).
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Intra-amygdalar injection of flumazenil selectively counteracts ethanol withdrawal-induced
anxiety-like behavior. Rats were implanted with cannulae above the amygdala and then
subjected to 3 cycles of 4.5% ethanol diet (ED3). Injections were given 4 hours after ethanol
from the first and second cycles of ED was withdrawn. Social-interaction behavior was
assessed between 5 and 6 hours after the removal of the third cycle of ethanol. CD, control diet
given to unoperated controls; ED3-Veh, ethanol diet with vehicle injections (artificial
cerebrospinal fluid); ED3-Flum, Ethanol diet and flumazenil injections (5 μg/μl per side). *p
< 0.05 versus CD-Veh.
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Dose–response for intra-amygdala flumazenil pretreatments that selectively counteract ethanol
withdrawal-induced anxiety-like behavior. Rats were implanted with cannulae above the
amygdala, exposed to 3 cycles of chronic ethanol diet with or without flumazenil pretreatments
(2.5, 5, or 10 μg/μl per side) during the first 2 withdrawals. Other groups and abbreviations are
as per Fig. 2. *p < 0.05 versus CD-Veh.
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Intra-raphe injection of flumazenil fails to counteract ethanol withdrawal- induced anxiety-like
behavior. Rats were implanted with single cannulae above the dorsal raphe nucleus and then
subjected to 3 cycles of 4.5% ethanol diet (ED3). Flumazenil treatment was 2.5 μg (0.5 μg/
μl). Groups and abbreviations are as per Fig. 2. *p < 0.05 versusCD-Veh.
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Intra-paraventricular nucleus of the hypothalamus injections of flumazenil fails to counteract
ethanol withdrawal-induced anxiety-like behavior. Rats were implanted with cannulae above
the paraventricular nucleus and then subjected to 3 cycles of 4.5% ethanol diet (ED3).
Flumazenil treatment was 2.5 μg (0.5 μg/μl). Groups and abbreviations are as per Fig. 2. *p <
0.05 versus CD-Veh.
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Intra-accumbens injections of flumazenil into the accumbens fail to counteract ethanol
withdrawal-induced anxiety-like behavior. Rats were implanted with cannulae above the
nucleus accumbens and then subjected to 3 cycles of 4.5% ethanol diet (ED3). Flumazenil
treatments, groups, and abbreviations are as per Fig. 2. *p < 0.05 versus CD-Veh.
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Failure of injections of flumazenil in the inferior colliculus to counteract ethanol withdrawal-
induced anxiety-like behavior. Rats were implanted with cannulae above the inferior colliculus
and then subjected to 3 cycles of 4.5% ethanol diet (ED3). Flum5 and Flum10 injections (5 or
10 μg/μl per side, respectively) were given 4 hours after ethanol from the first and second cycles
of ED was withdrawn. Other groups and abbreviations are as per Fig. 2. *p < 0.05 versus CD-
Veh.
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Repeated intra-amygdalar injection of methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-
carboxylate (DMCM) sensitizes ethanol withdrawal-induced anxiety-like behavior. Rats were
implanted with cannulae above the amygdala, treated with DMCM twice, and then subjected
to 1 cycle of 4.5% ethanol diet (ED1). Other groups and abbreviations are as per Fig. 2. *p <
0.05 versus CD-Veh.
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Peripheral pretreatment with flumazenil prevents sensitization of ethanol withdrawal-induced
anxiety-like behavior by intra-amygdala injection of methyl-6,7-dimethoxy-4-ethyl-β-
carboline-3-carboxylate (DMCM). Rats were implanted with cannulae above the amygdala,
treated with DMCM twice with or without flumazenil pretreatment (5 μg/μl per side), and then
subjected to 1 cycle of 4.5% ethanol diet (ED1). Other groups and abbreviations are as per Fig.
2. *p < 0.05 versusCD-Veh.
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Intra-amygdala pretreatment with flumazenil prevents sensitization of ethanol withdrawal-
induced anxiety-like behavior by restraint stress. Rats were implanted with cannulae above the
amygdala, restraint stressed twice with or without intra-amygdala flumazenil injection (5 μg/
μl per side), and then subjected to 1 cycle of 4.5% ethanol diet (ED1). Other groups and
abbreviations are as per Fig. 2. *p < 0.05 versus CD-Veh.
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Table 1
Body Weights and Ethanol Intakesa
Treatment group Ethanol intake (g/kg/d) Body weight (g)
Experiment 1: flumazenil/amygdala
 CD-Veh NA 344 ± 4
 ED3-Veh 8.2 ± 0.2 331 ± 8
 ED3-flumazenil 8.1 ± 0.4 332 ± 12
t(17) = 0.33; NS F(2,34) = 1.57; NS
Experiment 2: flumazenil/amygdala, dose–response
 CD-Veh NA 343 ± 5
 ED3-Veh 8.3 ± 0.5 335 ± 12
 ED3-flumazenil (2.5 μg per side) 7.8 ± 0.3 340 ± 7
 ED3-flumazenil (5 μg per side) 7.4 ± 0.4 338 ± 10
 ED3-flumazenil (10 μg per side) 7.9 ± 0.2 343 ± 5
F(3,16) = 1.01; NS F(4,22) = 0.13; NS
Experiment 3: flumazenil/raphe
 CD-Veh NA 300 ± 4
 ED3-Veh 8.4 ± 0.3 322 ± 8
 ED3-flumazenil 8.7 ± 0.3 334 ± 6
t(13) = 0.56; NS F(2,25) = 5.44, p < 0.01
Experiment 4: flumazenil/PVN
 CD-Veh NA 364 ± 5
 ED3-Veh 8.6 ± 0.5 335 ± 6
 ED3-flumazenil 8.7 ± 0.2 341 ± 6
t(14) = 0.02; NS F(2,21) = 7.07; p < 0.01
Experiment 5: flumazenil/accumbens
 CD-Veh NA 343 ± 7
 ED3-Veh 8.9 ± 0.7 327 ± 9
 ED3-flumazenil 8.7 ± 0.2 310 ± 12
t(11) = 0.15; NS F(2,18) = 3.27; NS
Experiment 6: flumazenil/colliculus
 CD-Veh NA 356 ± 4
 ED3-Veh 10 ± 0.6 358 ± 10
 ED3-flumazenil (5 μg per side) 9.5 ± 0.3 353 ± 8
 ED3-flumazenil (10 μg per side) 9.0 ± 0.5 335 ± 15
F(2,35) = 1.04; NS F(3,35) = 1.06; NS
Experiment 7: DMCM/amygdala
 CD-Veh NA 353 ± 4
 ED1-Veh 8.5 ± 0.2 347 ± 7
 ED1-DMCM 7.9 ± 0.3 348 ± 6
t(14) = 1.51; NS F(2,31) = 0.36; NS
Experiment 8: flumazenil DMCM
 CD-Veh NA 324 ± 6
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Treatment group Ethanol intake (g/kg/d) Body weight (g)
 ED1-Veh 8.6 ± 0.6 326 ± 7
 ED1-DMCM 9.0 ± 0.4 314 ± 5
 ED1-flumazenil-DMCM 8.7 ± 0.4 324 ± 6
F(2,21) = 0.23; NS F(3,35) = 0.49; NS
Experiment 9: flumazenil/amygdala stress
 CD-Veh NA 338 ± 7
 ED1-Veh 8.1 ± 0.2 335 ± 6
 ED1-flumazenil 7.7 ± 0.3 318 ± 0
t(22) = 1.17; NS F(2,26) = 4.15, p < 0.05
a
Rats consumed ethanol or control diets for one or three 5-day cycles with flumazenil treatments during periods of withdrawal at the end of the first
2 of 3 cycles (experiments 1 to 6), or prior to repeated DMCM treatment (experiments 7 to 8) or repeated stress (experiment 9).
NA, not applicable; NS, not significant; CD, control diet; ED, ethanol diet; PVN, paraventricular nucleus of the hypothalamus; ED1, ED3, 1 or 3
cycles of ethanol diet, respectively; DMCM, methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate.
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